Corporate Governance Statement
Released
Released
Announcement PDF
Corporate Governance Statement
Emerald Clinics Limited (Company) and the Board of Directors of the Company (Board) are
committed to achieving and maintaining high standards of performance and corporate
governance.
The Company supports the 4th Edition of the ASX Corporate Governance Council's Corporate
Governance Principles and Recommendations (Recommendations).
The Company's practices are largely consistent with the Recommendations. The Board considers
that the implementation of a small number of Recommendations is not appropriate, for the
reasons set out below in relation to the items concerned. The Board uses its best endeavours
to ensure that exceptions to the Recommendations do not have a negative impact on the
Company and the best interests of shareholders as a whole.
The directors of the Company (Directors, being either Non-Executive Directors or Executive
Directors) are responsible to the shareholders for the performance of the Company in both
the short and the longer term and seek to balance sometimes competing objectives in the best
interests of the Company as a whole. Their focus is to enhance the interests of shareholders
and other key stakeholders and to ensure the Company is properly managed.
As required by the ASX Listing Rules, the Company's main corporate governance policies and
practices are summarised below, having regard to the Recommendations.
Page 1
1.
Principle 1: Lay solid foundations for management and
oversight
1.1
Recommendation 1.1 - Board of Directors and Senior Management – Roles
and Responsibilities
A listed entity should have and disclose a board charter setting out:
(a)
the respective roles and responsibilities of its board and management;
and
(b)
those matters expressly reserved to the board and those delegated to
management.
The Board has adopted a formal charter that details the respective Board and
management functions and responsibilities (Board Charter).
A copy of the Board Charter is available on the Company’s website at
www.emeraldclinics.com.au.
1.2
Recommendation 1.2 - Board nominations
A listed entity should:
(a)
undertake appropriate checks before appointing a director or
senior executive or putting someone forward for election as a
director; and
(b)
provide security holders with all material information in its
possession relevant to a decision on whether or not to elect or
re-elect a director.
The Company considers the character, industry and relevant experience, education
and skill set, as well as interests and associations of candidates for appointment to the
Board and conducts appropriate checks to verify the suitability of the candidate, prior
to their appointment.
The Company ensures all information in relation to Directors seeking reappointment is
set out in the Directors report and Notice of Annual General Meeting.
1.3
Recommendation 1.3 - Directors and Senior Executives - Terms of
appointment
A listed entity should have a written agreement with each director and senior
executive setting out the terms of their appointment.
The Company maintains written agreements with each of its Directors and senior
executives setting out their roles and responsibilities.
Page 2
1.4
Recommendation 1.4 - Company Secretary
The company secretary of a listed entity should be accountable directly to the
board, through the chair, on all matters to do with the proper functioning of the
board.
As set out in the Board Charter the Company Secretary is engaged by the Company to
manage the proper functioning of the Board and reports directly to the Chair and is
accountable to the Board.
1.5
Recommendation 1. 5 - Diversity
A listed entity should:
(a)
have and disclose a diversity policy;
(b)
through its board or a committee of the board, set measurable objectives
for achieving gender diversity in the composition of its board, senior
executives and workforce generally; and
(c)
disclose in relation to each reporting period:
(1)
the measurable objectives set for that period to achieve gender
diversity;
(2)
the entity’s progress towards achieving those objectives; and
(3)
either:
(A)
the respective proportions of men and women on the
board, in senior executive positions and across the
whole workforce (including how the entity has defined
"senior executive" for these purposes); or
(B)
if the entity is a "relevant employer" under the
Workplace Gender Equality Act, the entity's most recent
"Gender Equality Indicators", as defined in and
published under the Act.
The Company has adopted a policy addressing the achievement of gender diversity,
however, given the current size of the Company’s operations, the Company has not set
measurable objectives for achieving gender diversity.
Should the setting of such measurable objectives be considered appropriate for the
Company in the future due to increases in size of the organisation, the Company will
look to adopt such objectives.
The Company's corporate code of conduct provides a framework for undertaking
ethical conduct in employment.
At each reporting date, the Company will disclose the respective proportions of men
and women on the Board, in senior executive positions and across the whole workforce
(including how the entity has defined 'senior executive' for these purposes).
Page 3
1.6
Recommendation 1.6 - Board performance review and evaluation
A listed entity should:
(a)
have and disclose a process for periodically evaluating the performance of
the board, its committees and individual directors; and
(b)
disclose for each reporting period whether a performance evaluation has
been undertaken in accordance with that process during or in respect of
that period.
The Board will review its performance annually, as well as the performance of
individual Committees and individual directors (including the performance of the
Chairman as Chairman of the Board)
The Company will disclose whether a performance evaluation was undertaken in each
reporting period.
1.7
Recommendation 1.7 - Senior executive performance review and evaluation
A listed entity should:
(a)
have and disclose a process for evaluating the performance of its senior
executives at least once every reporting period; and
(b)
disclose for each reporting period whether a performance evaluation has
been undertaken in accordance with that process during or in respect of
that period.
The Company has in place procedures for evaluating the performance of its senior
executives overseen by the Board. This evaluation is based on specific criteria,
including the business performance of the Company and its subsidiaries, whether
strategic objectives are being achieved and the development of management and
personnel.
The Company will disclose whether a performance evaluation was undertaken in each
reporting period.
Page 4
2.
Principle 2: Structure the Board to be effective and add
value
2.1
Recommendation 2.1 - Nomination committee
The board of a listed entity should:
(a)
have a nomination committee which:
(1)
has at least three members, a majority of whom are
independent directors; and
(2)
is chaired by an independent director,
and disclose:
(b)
(3)
the charter of the committee;
(4)
the members of the committee;
(5)
as at the end of each reporting period, the number of times the
committee met throughout the period and the individual
attendances of the members at those meetings; or
if it does not have a nomination committee, disclose that fact and the
process it employs to address board succession issues and to ensure that
the board has the appropriate balance of skills, knowledge, experience,
independence and diversity to enable it to discharge its duties and
responsibilities effectively.
The Company is not yet of a relevant size to consider the formation of a nomination
committee to deal with the selection and appointment of new Directors and as such a
nomination committee has not been formed.
Nominations of new Directors are considered by the full Board. If any vacancies arise
on the Board, all Directors are involved in the search and recruitment of a
replacement. The Board is confident that this process for selection, including
undertaking appropriate checks before appointing a person, or putting forward to
security holders a candidate for election, and review is stringent and full details of all
Directors will be provided to Shareholders in the annual report and on the Company's
website.
2.2
Recommendation 2.2 - Skills, knowledge and experience
A listed entity should have and disclose a board skills matrix setting out the mix
of skills that the board currently has or is looking to achieve in its membership.
The Board has established a Risk Matrix and will disclose its skills on a collective basis
in its annual corporate governance statement.
A profile of each Director setting out their skills, experience and period of office is set
out in the Directors' Report of the latest Annual Report.
Page 5
2.3
Recommendation 2.3 - Independence and length of service
A listed entity should disclose:
(a)
the names of the directors considered by the board to be independent
directors;
(b)
if a director has an interest, position or relationship of the type
described in Box 2.3 (Factors relevant to assessing the independence of
a director) but the board is of the opinion that it does not compromise
the independence of the director, the nature of the interest, position or
relationship in question and an explanation of why the board is of that
opinion; and
(c)
the length of service of each director.
The Board currently consists of Executive Directors Stewart Washer, Michael Winlo and
Alistair Vickery and Non-Executive Director Matthew Callahan. Mr Callahan is not
considered an independent Director due to an associated entity being a substantial
shareholder in the Company. Upon Admission, proposed Director John Tooke will join
the Board and be considered an independent Director. As the Company's activities
develop in size, nature and scope, the composition of the Board and the
implementation of additional corporate governance policies and structures will be
reviewed.
Dr Stewart Washer and Mr Mathew Callahan were appointed directors on 19 March
2018. Ms Patrizia Washer was appointed on 19 March 2019 and resigned on 28 October
2019. Mr Alistair Vickery was appointed on 18 March 2019. Michael Winlo was appointed
on 7 November 2019.
2.4
Recommendation 2.4 - Majority of independent Directors
A majority of the board of a listed entity should be independent directors.
Due to the size and scale of the Company's current activities, the Board does not
consist of a majority of independent directors. The Board considers the composition
of the Board, is appropriate given the size and current operations of the Company.
To further facilitate independent decision-making, the Board has agreed procedures
for Directors to have access in appropriate circumstances to independent
professional advice.
As the Company grows, the Board will consider the appointment of additional
independent Directors
2.5
Recommendation 2.5 - Independent Chair
The chair of the board of a listed entity should be an independent director and,
in particular, should not be the same person as the CEO of the entity.
The Board has formed the view that, given the size and nature of the business of the
Company, and the knowledge and experience Dr Stewart Washer brings to the
Company, that Dr Washer is the most appropriate person to hold the position of
Chairman of the Company even though he is not independent by reason of being an
Executive Director. The Chairman is not the same person as the CEO of the entity. As
the Company grows, the Board will consider the appointment of additional
independent Directors.
Page 6
2.6
Recommendation 2.6
A listed entity should have a program for inducting new directors and for
periodically reviewing whether there is a need for existing directors to
undertake professional development to maintain the skills and knowledge
needed to perform their role as directors effectively.
Upon appointment to the Board new Directors will be provided with Company policies
and will be provided an opportunity to discuss the Company's operations with senior
management and the Board.
The Company encourages its Directors to participate in professional development
opportunities presented to the Company and provides appropriate industry information
to its Board members on a regular basis.
3.
Principle 3: Instil a culture of acting lawfully, ethically
and responsibly
3.1
Recommendation 3.1 - Statement of values
A listed entity should articulate and disclose its values.
The Board has approved a statement of values and charges the Directors with the
responsibility of inculcating those values across the Company.
A copy of the Company's statement of values is available on the Company's website,
www.emeraldclinics.com.au.
3.2
Recommendation 3.2 - Code of conduct
A listed entity should:
(a)
have and disclose a code of conduct for its directors, senior executives
and employees; and
(b)
ensure that the board or a committee of the board is informed of any
material breaches of that code.
The Company has established a Code of Conduct that sets out the principles covering
appropriate conduct in a variety of contexts and outlines the minimum standards of
behaviour expected from its Directors and employees. The Code of Conduct sets out
policies in relation to various corporate and personal behaviour including safety,
discrimination, respecting the law, anti-corruption, interpersonal conduct and conflict
of interest.
A copy of the Company's Code of Conduct is available on the "Corporate Governance"
page of the Company's website, www.emeraldclinics.com.au.
3.3
Recommendation 3.3 - Whistleblower policy
A listed entity should:
(c)
have and disclose a whistleblower policy; and
Page 7
(d)
ensure that the board or a committee of the board is informed of any
material incidents reported under that policy.
The Board has adopted a Whistleblower Protection Policy to ensure concerns regarding
unacceptable conduct including breaches of the Company's code of conduct can be
raised on a confidential basis, without fear of reprisal, dismissal or discriminatory
treatment. The purpose of this policy is to promote responsible whistle blowing about
issues where the interests of others, including the public, or of the organisation itself
are at risk.
A copy of the Company's Whistleblower Protection Policy is available on the Company's
website, www.emeraldclinics.com.au.
3.4
Recommendation 3.4 Anti-bribery and corruption policy
A listed entity should:
(e)
have and disclose an anti-bribery and corruption policy; and
(f)
ensure that the board or a committee of the board is informed of any
material breaches of that policy.
The Board has adopted an Anti-Bribery and Anti-Corruption Policy for the purpose of
setting out the responsibilities in observing and upholding the Company's position on
bribery and corruption provide information and guidance to those working for the
Company on how to recognise and deal with bribery and corruption issues.
A copy of the Company's Anti-Bribery and Anti-Corruption Policy is available on the
Company's website, www.emeraldclinics.com.au.
4.
Principle 4: Safeguard the integrity of corporate reports
4.1
Recommendation 4.1 - Audit committee
The board of a listed entity should:
(a)
have an audit committee which:
(1)
has at least three members, all of whom are non-executive
directors and a majority of whom are independent directors;
and
(2)
is chaired by an independent director, who is not the chair of
the board,
and disclose:
(3)
the charter of the committee;
(4)
the relevant qualifications and experience of the members of
the committee; and
(5)
in relation to each reporting period, the number of times the
committee met throughout the period and the individual
attendances of the members at those meetings; or
Page 8
(b)
if it does not have an audit committee, disclose that fact and the
processes it employs that independently verify and safeguard the
integrity of its corporate reporting, including the processes for the
appointment and removal of the external auditor and the rotation of the
audit engagement partner.
The Board considers that the Company is not currently of a size, nor are its affairs of
such complexity requiring the formation of a separate Audit Committee.
The full Board carries out the duties that would ordinarily be assigned to the Audit
Committee.
4.2
Recommendation 4.2 - CEO and CFO declarations
The board of a listed entity should, before it approves the entity's financial
statements for a financial period, receive from its CEO and CFO a declaration
that, in their opinion, the financial records of the entity have been properly
maintained and that the financial statements comply with the appropriate
accounting standards and give a true and fair view of the financial position and
performance of the entity and that the opinion has been formed on the basis of
a sound system of risk management and internal control which is operating
effectively.
The Company will, before it approves the entity’s financial statements for a full year
and half year financial period, receive from its CEO and CFO a declaration that, in
their opinion, the financial records of the entity have been properly maintained and
that the financial statements comply with the appropriate accounting standards and
give a true and fair view of the financial position and performance of the entity and
that the opinion has been formed on the basis of a sound system of risk management
and internal control which is operating effectively. The Board has formed the view
that, given the size and nature of the business of the Company, such a process is not
required in relation to the Company's quarterly cash flow reports.
4.3
Recommendation 4.3 - Periodic corporate reports
A listed entity should disclose its process to verify the integrity of any periodic
corporate report it releases to the market that is not audited or reviewed by an
external auditor.
When preparing reports for release to the market including the quarterly activity and
cash flow reports these reports shall be prepared and reviewed by the Managing
Director before being presented to the Board for review. Such reports shall not be
released to market without this review process by the managing Director and the
Board.
5.
Principle 5: Make timely and balanced disclosure
5.1
Recommendation 5.1 - Continuous disclosure to ASX
A listed entity should have and disclose a written policy for complying with its
continuous disclosure obligations under ASX Listing Rule 3.1.
The Company has established a Continuous Disclosure Policy which is designed to guide
compliance with ASX Listing Rule disclosure requirements, and to ensure that all
Page 9
Directors, senior executives and employees of the Company understand their
responsibilities under the policy.
In accordance with the Company's Continuous Disclosure Policy, all information
provided to ASX for release to the market is also posted to the Company's website,
www.emeraldclinics.com.au.
The Continuous Disclosure Policy of the Company is available on the "Corporate
Governance" page of the Company's website www.emeraldclinics.com.au.
5.2
Recommendation 5.2 - Copies of market announcements
A listed entity should ensure that its board receives copies of all material market
announcements promptly after they have been made.
The Board has appointed the Company Secretary as the person responsible for
communicating with ASX and overseeing and coordinating the timely disclosure of
information to ASX. The Company Secretary will ensure that when the confirmation of
a release is received from the ASX, it is promptly forwarded to the Board.
5.3
Recommendation 5.3 - Presentation materials
A listed entity that gives a new and substantive investor or analyst presentation
should release a copy of the presentation materials on the ASX Market
Announcements Platform ahead of the presentation.
The Board has appointed the Company Secretary as the person responsible for
communicating with ASX and overseeing and coordinating the timely disclosure of
information to ASX. The Company Secretary will ensure that any new and substantive
presentations are released to the ASX Market Announcements Platform ahead of the
presentation and a copy of which is available on the Company's website,
www.emeraldclinics.com.au.
6.
Principle 6: Respect the rights of security holders
6.1
Recommendation 6.1 - Information available on the Company's website
A listed entity should provide information about itself and its governance to
investors via its website.
The Company’s website at www.emeraldclinics.com.au contains information about the
Company’s activities, Directors and management and the Company’s corporate
governance practices, policies and charters. All ASX announcements made to the
market, including annual and half year financial results are posted on the website as
soon as they have been released by the ASX. The full text of all notices of meetings
and explanatory material, the Company’s Annual Report and copies of all investor
presentations are posted on the website.
6.2
Recommendation 6.2 - Investor relations
A listed entity should have an investor relations program that facilitates effective
two-way communication with investors.
The Company has adopted a Shareholder Communication Policy, which encourages
shareholder participation and engagement with the Company. This policy has
Page 10
nominated the Chair, Managing Director and Company Secretary for having the primary
responsibility for communicating with shareholders.
The Company actively promotes communication with shareholders through a variety of
measures, including the use of the Company's website and email. The Company's
reports and ASX announcements may be viewed and downloaded from its website,
www.emeraldclinics.com.au, or the ASX website, www.asx.com.au under the ASX code
"[EMD]".
6.3
Recommendation 6.3 - Shareholders' meetings
A listed entity should disclose how it facilitates and encourages participation at
meetings of security holders.
The Shareholder Communication Policy encourages shareholder participation at
shareholders' meetings. Shareholders are provided with all notices of meeting prior to
meetings. The Company's auditor is also made available for questions at the annual
general meeting. Shareholders are also always given the opportunity to ask questions
of the Directors and management, either during or after shareholders' meetings.
6.4
Recommendation 6.4 - Resolutions decided by a poll
A listed entity should ensure that all substantive resolutions at a meeting of
security holders are decided by a poll rather than by a show of hands.
The Company will conduct a poll at meetings of security holders to decide each
resolution.
6.5
Recommendation 6.5 - Electronic communications
A listed entity should give security holders the option to receive communications
from, and send communications to, the entity and its security registry
electronically.
Contact with the Company can be made via an email address provided on the website
and investors can subscribe to the Company’s mailing list.
The Company’s share register provides a facility whereby investors can provide email
addresses to receive correspondence from the Company electronically and investors
can contact the share register via telephone, facsimile or email.
7.
Principle 7: Recognise and manage risk
7.1
Recommendation 7.1 - Risk committee
The board of a listed entity should:
(a)
have a committee or committees to oversee risk, each of which:
(1)
has at least three members, a majority of whom are
independent directors; and
(2)
is chaired by an independent director,
and disclose:
(3)
the charter of the committee;
Page 11
(b)
(4)
the members of the committee; and
(5)
as at the end of each reporting period, the number of times the
committee met throughout the period and the individual
attendances of the members at those meetings; or
if it does not have a risk committee or committees that satisfy (a) above,
disclose that fact and the processes it employs for overseeing the entity's
risk management framework.
The Board's collective experience will assist in the identification of the principal risks
that may affect the Company's business. Key operational risks and their management
will be recurring items for deliberation at Board meetings.
A Risk Committee has been established by the Board. Members of the Risk Committee
will be John Tooke (Chair) Matthew Callahan and Stewart Washer.
The qualifications and experience of the members of the Risk Committee will be
disclosed in the Directors’ Report contained in the Annual Report.
As a consequence of the size and composition of the Company's Board the Risk
Committee does not have a majority of independent Directors as per the
Recommendations.
7.2
Recommendation 7.2 - Internal control
The board or a committee of the board should:
(a)
review the entity's risk management framework at least annually to
satisfy itself that it continues to be sound and that the entity is operating
with due regard to the risk appetite set by the board; and
(b)
disclose, in relation to each reporting period, whether such a review has
taken place.
The Company is committed to the identification; monitoring and management of risks
associated with its business activities and has established policies in relation to the
implementation of practical and effective control systems. The Company has
established a Risk Management Framework and Policy.
The Company will disclose annually whether the Board has completed a review of the
Company’s Risk Management Framework and Policy to satisfy itself that it continues
to be sound and applicable to the Company’s activities.
7.3
Recommendation 7.3 - Internal audit
A listed entity should disclose:
(a)
if it has an internal audit function, how the function is structured and
what role it performs; or
(b)
if it does not have an internal audit function, that fact and the processes
it employs for evaluating and continually improving the effectiveness of
its governance, risk management and internal control processes.
The Company does not have an independent internal audit function. Due to the nature
and size of the Company's operations, and the Company's ability to derive substantially
Page 12
all of the benefits of an independent internal audit function in the manner disclosed
below, the expense of an independent internal auditor is not considered to be
appropriate.
The Board, in conjunction with the Risk Committee, oversees the Company’s risk
management systems, practices and procedures to ensure effective risk identification
and management and compliance with internal guidelines and external requirements
and monitors the quality of the accounting function.
7.4
Recommendation 7.4 - Risk management
A listed entity should disclose whether it has any material exposure to
environmental or social risks and, if it does, how it manages or intends to manage
those risks.
The Company identifies and manages material exposure to environmental and social
risks in a manner consistent with its Risk Management Framework and Policy.
Environmental: The Company is subject to, and responsible for, ensuring compliance
with various regulations, licenses, approvals and standards so that its activities do not
cause unauthorised environmental harm. Through its ongoing management of
environmental activities, the Company has been able to operate in an environmentally
sustainable and responsible manner.
Social: The Company recognises that a failure to manage stakeholder expectations
may lead to disruption to the Company’s operations. The Company’s Corporate Code
of Conduct outlines the Company's commitment to integrity and fair dealing in its
business affairs and to a duty of care to all employees, clients and stakeholders.
8.
Principle 8: Remunerate fairly and responsibly
8.1
Recommendation 8.1 - Remuneration committee
The board of a listed entity should:
(a)
have a remuneration committee which:
(1)
has at least three members, a majority of whom are
independent directors;
(2)
is chaired by an independent director,
and disclose:
(b)
(3)
the charter of the committee;
(4)
the members of the committee; and
(5)
as at the end of each reporting period, the number of times the
committee has met throughout the period and the individual
attendances of the members at those meetings; or
if it does not have a remuneration committee, disclose that fact and the
processes it employs for setting the level and composition of
remuneration for directors and senior executives and ensuring that such
remuneration is appropriate and not excessive.
Page 13
The Board as a whole performs the function of a remuneration committee which
includes setting the Company's remuneration structure, determining eligibilities to
incentive schemes, assessing performance and remuneration of senior management
and determining the remuneration and incentives of the Board.
The Board considers that the Company is not currently of a size, nor are its affairs of
such complexity requiring the formation of a separate remuneration committee.
The Board may obtain external advice from independent consultants in determining
the Company's remuneration practices, including remuneration levels, where
considered appropriate.
8.2
Recommendation 8.2 - Remuneration policy
A listed entity should separately disclose its policies and practices regarding the
remuneration of non-executive directors and the remuneration of executive
directors and other senior executives.
The remuneration of any Executive Director will be decided by the Board, without the
affected Executive Director participating in that decision-making process.
A Non-Executive Director may be paid fees or other amounts in accordance w
Share your feedback
Discover